Business
Freenome and Perceptive Capital Solutions Corp Announce Business Combination Agreement to Create a Publicly Listed Company Transforming Blood-Based Multi-Cancer Detection through an AI/ML-Enabled Multiomics Platform
Freenome Holdings, Inc., an early cancer detection company developing blood-based screening tests, and Perceptive Capital Solutions Corp (Nasdaq: PCSC), a special purpose acquisition company (SPAC) sponsored by an affiliate of Perceptive Advisors, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, PCSC will redomicile as a Delaware corporation, be renamed Freenome, Inc., and its common stock is expected to be listed on Nasdaq
About this update from Perceptive Capital Solutions Corp
[{"type":"text","content":"– Leading institutional investors commit $240 million through private investment in public equity (PIPE) led by Perceptive Advisors and RA Capital – ","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"– Freenome stockholders, PCSC shareholders and PIPE investors will hold shares in the Combined Company that is expected to be listed on Nasdaq under the ticker symbol FRNM –","length":173,"tagName":"p","attribs":{}},{"type":"text","content":"– Business combination is expected to be completed in the first half of 2026 –","length":78,"tagName":"p","attribs":{}},{"type":"text","content":"BRISBANE, Calif. and NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Freenome Holdings, Inc., an early cancer detection company developing blood-based screening tests, and Perceptive Capital Solutions Corp (Nasdaq: PCSC), a special purpose acquisition company (SPAC) sponsored by an affiliate of Perceptive Advisors, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, PCSC will redomicile as a Delaware corporation, be renamed Freenome, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol "FRNM" (the "Combined Company").","length":637,"tagName":"p"},{"type":"image","alt":"Freenome is a biotechnology company pioneering an early cancer detection platform. (PRNewsfoto/Freenome Holdings, Inc.)","displaySize":"","headline":null,"caption":"Freenome is a biotechnology company pioneering an early cancer detection platform. (PRNewsfoto/Freenome Holdings, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":62,"url":"https://media.zenfs.com/en/prnewswire.com/a749e5e333ab97e4cbda5657c477e787"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/EnqV5upUyoryjpM8L0tjMA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a749e5e333ab97e4cbda5657c477e787","width":400,"height":62}},"href":"https://mma.prnewswire.com/media/1934326/Freenome_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In addition to approximately $90 million held in PCSC's trust account (assuming no redemptions by PCSC's public shareholders), the transaction includes commitments for a common equity PIPE at $10.00 per share of approximately $240 million from a gr...